Evidence map›Paper›PMID 40628790›Full record

ArticleScientific reports2025

Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia.

Yuyang Wang, Yibing Guo, Xiuxin Ling, Junhui Li, Tao Hu, Zhaoxia Zhang, Mengze Hu, Zeliang Song, Mei Yue, Ruihong Tang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuyang WangDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Yibing GuoBioengineering, Beijing, China.
Xiuxin LingBioengineering, Beijing, China.
Junhui LiDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Tao HuDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Zhaoxia ZhangDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Mengze HuDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Zeliang SongDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Mei YueDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Ruihong TangDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Dixiao ZhongDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China.
Rong LiuDepartment of Hematology, Capital Center for Children's Health, Capital Medical University, Chaoyang District, Beijing, 100020, China. liu_rong_doctor@163.com.

Funding

Capital Health Research and Development of Special 2022-1-2091
6 · The paper itself

Abstract

Acute Myeloid Leukemia (AML) in infants constitutes a rare and biologically distinct subgroup. Hematopoietic stem cell transplantation (HSCT) plays a pivotal role in the treatment of infant AML. However, the source of stem cells remains insufficiently explored. This study aimed to evaluate the clinical outcomes of allogeneic HSCT from different sources. We conducted a single-center retrospective analysis of 27 infants with AML who underwent HSCT. We compared peripheral blood (PB) with/without bone marrow (BM) (Group 1, n = 16) versus umbilical cord blood (UCB) (Group 2, n = 12). There was no significant difference in 3-year overall survival (OS), disease-free survival (DFS), 3-year recurrence rates, or one-year cumulative graft-versus-host disease (GVHD) incidence between two groups (3-year OS: 80.36% for group 1 vs. 91.67% for group 2, p = 0.5474; DFS: 73.66% vs. 69.84%, p = 0.8232; GVHD: 56.25% for group 1 vs. 50.0% for group 2, p = 0.824). The group with pre-transplant minimal residual disease (MRD) status had a lower recurrence rate. This study emphasizes the efficacy of HSCT in the treatment of infant AML, with higher OS rates compared to childhood AML. It also supports UCB as a viable stem cell source. Achieving MRD-negative status before transplantation is crucial for improving post-transplant outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansInfantMaleNeoplasm, ResidualRetrospective StudiesTransplantation, HomologousTreatment OutcomeAcute myeloid leukemiaHematopoietic stem cell transplantationRecurrence ratesSurvival

Identifiers

PMID40628790
PMCPMC12238306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.